Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02713828 · ClinicalTrials.gov registry record · Phase 1
Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
A Phase 1 study, sponsored by PrECOG.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT02713828 is a Phase 1 study that was terminated before completion, run by PrECOG. The registered enrollment target is 13 participants.
The verdict
NCT02713828, a Phase 1 study, was terminated before completion, sponsored by PrECOG.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
Patients with advanced or metastatic, gpNMB-expressing Squamous Cell Carcinoma (SCC) of the lung who have failed a prior platinum-based chemotherapy regimen will receive glembatumumab vedotin. Glembatumumab vedotin consists of an antibody (a type of human protein) attached to a drug called Monomethyl Auristatin E (MMAE) that can kill cancer cells. Glembatumumab vedotin is intended to work by specifically directing the drug to the cancer cell. It attaches to a molecule on the cancer cell called gpNMB, and then releases the MMAE inside the tumor cell, which in turn causes the cell to die. The purpose of this study is to see whether glembatumumab vedotin is effective in treating people who have advanced or metastatic squamous cell lung cancer that contains gpNMB, to examine how the body handles the drug and the side effects associated with glembatumumab vedotin.
Interventions
- DRUG Phase I: Glembatumumab Vedotin
- DRUG Phase II: Glembatumumab Vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-04-10 |
| Est. Completion | 2018-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02713828
The ClinicalTrials.gov registry entry for NCT02713828 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PrECOG, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Phase I: Glembatumumab Vedotin is the first listed.
NCT02713828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02713828 about?
NCT02713828 is a clinical study titled "Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung". Patients with advanced or metastatic, gpNMB-expressing Squamous Cell Carcinoma (SCC) of the lung who have failed a prior platinum-based chemotherapy regimen will receive glembatumumab vedotin. Glembatumumab vedotin consists of an antibody (a type of human protein) attached to a drug called Monometh...
What is the current status of trial NCT02713828?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2016-04-10. Estimated completion is 2018-09-26.
What interventions are being tested in trial NCT02713828?
The interventions under investigation include: Phase I: Glembatumumab Vedotin (DRUG), Phase II: Glembatumumab Vedotin (DRUG).
Who is sponsoring clinical trial NCT02713828?
This trial is sponsored by PrECOG, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.